Methods:Patients with locally advanced NPC were enrolled into a prospective, dose escalating phase I study.
方法:局部晚期鼻咽癌患者随机进入前瞻性临床I期试验。
The phase I study clearly showed the low toxicity of the method and the accumulation of the MMS in the target area.
i期临床研究清楚地显示,此种治疗方法是低毒性的,而且MMS能在靶区内积聚。
Yang JCH, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a Phase I study.
osimertinib在非小细胞肺癌(NSCLC)所致软脑脊膜(LM)病患者(pts)中的活性:BLOOM I期研究的更新结果。
应用推荐